NCT06522360 2025-04-24
Brigatinib Plus Chemotherapy or Local Consolidation Therapy in ALK Positive Advanced Non-small Cell Lung Cancer (BrightStar-2)
M.D. Anderson Cancer Center
Phase 2 Withdrawn
Clinical Trials
3 trialsNCT03868423 2022-02-18
Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers
Ohio State University Comprehensive Cancer Center
Phase 2 Withdrawn
NCT03719898 2021-01-05
Brigatinib in Relapsed or Refractory ALK-Positive Anaplastic Large Cell Lymphoma
Fox Chase Cancer Center
Phase 2 Withdrawn